New Analytical Validation Confirms Accuracy and Precision of MyProstateScore 2.0

Study finds MPS2 scores are highly reproducible across DRE and non-DRE urine samples alike.

ANN ARBOR, Mich., April 7, 2025 /PRNewswire/ — Lynx Dx, a leader in innovative diagnostic solutions, announces the publication of a comprehensive analytical validation study of its flagship test, MyProstateScore 2.0 (MPS2), in the peer-reviewed journal Diagnostics. The results confirm the test’s strong analytical performance in detecting prostate cancer biomarkers from both post-digital rectal exam (DRE) and non-DRE urine samples—solidifying MPS2’s utility across in-office and at-home testing settings.

The publication complements earlier clinical validation studies, including a 2024 study in JAMA Oncology and a 2025 study in the Journal of Urology, both of which demonstrated that MPS2 significantly outperforms PSA-based screening and conventional clinical factor models in identifying patients at risk for clinically significant prostate cancer.

“This study reinforces the value of MPS2 as a non-invasive diagnostic tool that delivers consistent and precise results,” said Dr. Spencer Heaton, Chief Medical Officer at Lynx Dx. “By demonstrating robust analytical performance, MPS2 continues to be validated as a reliable option for prostate cancer risk assessment across diverse clinical workflows.”

MPS2 is a urine-based test that measures 18 prostate cancer-related biomarkers to assess a man’s risk of harboring clinically significant prostate cancer. The analytical validation showed that all 18 biomarkers met stringent criteria for linearity, precision, and detection sensitivity.

The study, which was based on Clinical Laboratory & Standards Institute guidelines, also confirmed high reproducibility of MPS2 scores and analyte detection with minimal interference from common urinary substances—demonstrating the test’s reliability in real-world conditions.

About MyProstateScore 2.0 (MPS2)
MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing expression of 18 unique gene transcripts, including the T2:ERG gene fusion, the most specific biomarker for prostate cancer. The test optimizes diagnostic accuracy for both biopsy naïve patients and those with a prior negative biopsy. Additionally, it provides diagnostic flexibility with optional assessment of personalized risk factors known to influence the development of clinically significant prostate cancer.

About Lynx Dx
Building off technology developed at the University of Michigan, Lynx Dx provides best-in-class diagnostic testing services to help people live healthy and productive lives. The company’s mission is to develop superior genomic tests where there is clear patient need. Lynx Dx produces tests with the highest degree of accuracy and efficiency combined with unparalleled customer experience. For more information about Lynx Dx and MyProstateScore 2.0, please visit www.lynxdx.com.

Media contact
Chad Van Alstin
public.relations@lynxdx.com
847-809-0406

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-analytical-validation-confirms-accuracy-and-precision-of-myprostatescore-2-0–302421153.html

SOURCE Lynx Dx